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Chapter 1: Herbal Supplements – A Personal Tradition 
 
Growing up as a Vietnamese-American, I am well versed in the idea of cultural 
differences. Early on, I realized that culture permeates everything – including the way we 
approach our health. In many ways, the dichotomy between Western and Eastern 
medicine mimics the contrast between the different cultures. I experienced this first hand 
with my grandma. To this day, her medicine cabinet remains stock full. Granted, about 
half of this cabinet is filled with prescription medications, over the counter drugs, and 
multi-vitamins. However, the other half is filled with herbal supplements. Many of these 
herbal supplement bottles are brightly decorated with CGI images of human anatomy or 
with a photo of an unspecified plant and most, if not all, contain non-descriptive names 
such as “Kidney” or “Livertox.” The vague descriptions and the limited ingredients list 
raised a lot of questions about the safety and efficacy of these supplements. While I 
remained wary and skeptical about these herbal remedies, I became aware of the wide 
range of possible physiological effects of these supplements. My grandma introduced me 
to a different side of medicine, one often ignored by researchers and providers.  
While traditional western medicine often excludes alternative or Eastern 
medicine, many people worldwide rely on complementary alternative medicine (CAM) 
which can include herbal supplements, dietary supplements, acupuncture, among other 
therapies. A significant number of women worldwide use these natural therapies at least 
once during their reproductive age. Interestingly, women who use CAM and herbal 
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remedies tend to be 31-40 years old with higher education levels and higher income 
levels, (Kennedy, Lupattelli, Koren, & Nordeng, 2013). The uptick in alternative 
medicine can be attributed to a multitude of different factors. Women often cite that 
alternative medicine techniques such as herbal medication promotes holistic health care 
by introducing the use of natural products, a method they prefer to the clinical side of 
Western medicine. Herbal therapy proponents hold that these natural therapies exist in a 
separate category compared to pharmaceutical or OTC drugs and appear to be 
synonymous to safe (Warriner et al., 2014). Using the power of the internet and personal 
testimonies, the surge in CAM and herbal supplement use continues into the current day.  
Currently, there are thousands of herbal supplements readily available to the 
general public and due to a little niche in FDA regulation, these supplements remain 
largely unregulated and unstandardized. In comparison, thousands of over the counter 
medications and pharmacological drugs exist, but many of these substances may be 
limited via prescriptions. Given their accessibility and increasing popularity, many 
women take a combination of pharmacological drugs and herbal supplement. The use of 
one or both methods are evident during pregnancy because women experience a whole 
slew of different symptoms. However, unregulated combinations result in potential herbal 
and pharmacological interactions, leading to a host of unintended physiological and 
biochemical effects on the maternal and fetal system. I believe that pregnant women need 
a comprehensive guide on how to navigate this complicated system. Women should be 
aware of the benefits, adverse side effects, and the possible interactions of both 
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pharmacological methods and herbal remedies, which allows them to make an informed 
decision on the course of their healthcare.  
Throughout the course of this thesis, I will comment on current Federal Food and 
Drug Administration (FDA) guidelines on the regulation of herbal supplements and 
compare them to international guidelines. I will elucidate on how gaps in these 
regulations can be detrimental to the health of patients and use this as a platform to 
introduce an extensive guide denoting the major biochemical changes occurring 
antepartum and postpartum as an explanation for symptoms often experienced during 
pregnancy. I will then use this as a background to detail the mechanism of the active 
ingredients in these supplements and comment on the effectiveness of the relating FDA 
regulations. I hope that this thesis will help raise awareness about common herbal 
supplements and serve as a resource grounded in scientific facts for women looking into 
alternative medicine during pregnancy.  
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Chapter 2: Differential Regulation of Pharmaceutical Drugs and Herbal 
Supplements Creates a Public Health Hazard 
 
International Laws and Regulation  
 The use of herbal supplements originated in the East, and currently, 
countries all over the world employ alternative medicine, especially the use of herbal 
supplements to treat certain ailments. In such a global society, the exchange of data 
information and regulatory remains a major part of international communication. While 
the World Health Organization (WHO) isn’t an official regulator of herbal medication 
and supplements, this association serves as a hub for information exchange regarding 
different national regulations. The WHO also supports the International Regulatory 
Cooperation for Herbal Medication (IRCH), an organization developed in 2006 by 
several countries who expressed interest in sharing research and regulatory issues. The 
IRCH, whose main purpose includes providing a global network of regulatory authorities 
responsible for regulating and promoting herbal supplements, includes 33 national and 
regional members who conduct annual meetings to discuss issues revolving around 
herbal medication and complementary medicine (Alostad, Steinke, & Schafheutle, 2018).   
From the importation of herbal plants and supplements to their distribution, the 
regulation of these substances takes on different faces across the globe. For example, 
Germany has a well-established regulatory and registration system that even predates the 
policy enforced by the European Union. As a result, some reports suggest that 
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approximately 70% of German physicians claim to feel confident in prescribing herbal 
medications to their patients. In contrast, India lacks a reliable regulation system. The 
mainframe of their system relies on poorly enforced policies and manufacturers can take 
advantage of many loopholes (Alostad et al., 2018). In comparison to many other 
countries, the United States employs a rather simplistic and broad approach towards 
regulation of these substances. Countries such as Germany and the UK have employed a 
more structured and reasoned system for registering herbal supplements and medication 
as seen in Figure 1. The United States differs from the structure and order of these 
different regulation systems in three main categories: evidence for safety and efficacy as 
well as registration requirements.  
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Figure 1. Summary comparison of herbal medication registration and regulation requirements 
set by the different regulatory agencies of the UK, USA, United Arab Emirates, Germany, and the 
Kingdom of Bahrain. This table looked at the differences between evidence requirements and 
labeling requirements between these countries. Figure adapted from Alostad, A. H., Steinke, D. 
T., & Schafheutle, E.I. (2018). International Comparison of Five Herbal Medicine Registration 
Systems to Inform Regulation Development: the United Kingdom, United States of America, 
United Arab Emirates and the Kingdom of Bahrain. Pharmaceutical Medicine, 32 (1), 39-49. 
Doi:10.1007/s40290-018-0223-0.  
 
 
 
17 
 
Perhaps most notably, as Figure 1 denotes, the regulatory authority in the U.S. or 
the FDA requires no evidence for safety, efficacy, or efficiency for dietary and herbal 
supplements. Conversely, many other countries require herbal medication to adhere to 
pre-marketing registration laws including laboratory standards, manufacturing standards, 
and storage requirements. Without the requirement for pre-marketing evaluation, the 
United States sets up a system where FDA intervention doesn’t begin until the herbal 
supplement enters the market and proves to be detrimental to patient health. This almost 
backward approach disavows any change for preventative regulation of herbal 
medications and leaves the door open for loopholes that manufacturers can take 
advantage of. The US notably requires no evidence from herbal manufactures or sellers 
other than a disclaimer on the box or bottle. In contrast, all of the other 4 countries used 
in this study require at least some form of validation for each of the main registration 
components.  
Secondly, the United States employs different registration requirements compared 
to its international counterparts. In countries apart of the European Union, herbal 
supplements and medication registered by the one-member state will be accepted by all 
other states in the union. However, under this directive, each member’s regulatory agency 
will employ pre-marketing checks and quality assessment. This system tried to ensure 
that each country can benefit from these herbal medications while also maintaining the 
proper quality assessments. Countries such as Germany also consider traditional usage as 
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evidence of efficacy, thus reducing the need for extensive clinical trials to validate their 
efficacy (Alostad et al., 2018). In the U.S., herbal supplements can make certain 
nutritional support claims, however, should a supplement claim to treat or cure a disease, 
it will be regarded as a botanical drug and undergo the same rigid requirements and 
standards imposed on conventional drugs. Because of this, between 2004 and 2013, only 
two botanical drugs have received FDA approval out of over 400 applicants (Avigan, 
Mozersky, & Seeff, 2016). Given the drastic differences between FDA policies and 
foreign policies, we will take a closer look into the specific policies that regulate dietary 
and herbal supplements.  
History of FDA Regulation  
 
The FDA is a regulatory agency for food and drugs in the U.S. Established by 
Harvey Washington Wiley, the head of the Bureau of Chemistry in the Department of 
Agriculture, this agency enforced regulations regarding the safety and quality of food 
products and pharmaceutical drugs. Prior to its establishment, the 1800s gave rise to a 
corrupt food and drug market. Many products sold during this era boasted claims with no 
backing and most commodities failed to disclose all of the ingredients in the product 
(Seamon & Clauson, 2005). The height of the crisis came in the form of the 1906 novel 
The Jungle, where Upton Sinclair elucidated the adulteration issues in the food industry, 
particularly the meat industry. With the public’s attention focused on the unsanitary 
conditions of food preparation and the danger of mislabeling, Congress passed the Pure 
 
 
19 
 
Food and Drug Act, which prohibited the misbranding and adulteration of food and drug 
products. In 1938, the government passed the FDCA (Food, Drug, and Cosmetic Act) to 
further elucidate the regulations placed on manufacturers and distributors. Under this act, 
no new drug can be marketed until it passes safety benchmarks set by the FDA and labels 
are required to contain adequate instructions and warnings. The 1938 bill also broadened 
the scope of the FDA to encompass cosmetics and therapeutic devices and therapies. Just 
two years after the enactment of this policy, the FDA issued dozens of safety warnings 
against various drug products and even deemed some products unsafe for distribution 
(Chhabra, Kremzner, & Kiliany, 2005). This bill creates the foundation for current food 
and drug regulation, and the FDA continues to modify and adjust its regulatory principles 
and systems today (Spies, 2006).  
DSHEA: Distinguishing Herbal Supplements from Pharmacological Drugs  
 
On October 25, 1994, President Bill Clinton passed the Dietary Supplement 
Health Education Act of 1994 (DSHEA) to establish standards for dietary and herbal 
supplements. The act starts in Section 3 by defining dietary and herbal supplements by 
law through a very rigid and specific definition:  
“(1) means a product (other than tobacco) intended to supplement the diet that 
bears or contains one or more of the following dietary ingredients:  
▪ “(A) a vitamin; 
▪ “(B) a mineral; 
▪ “(C) an herb or other botanical; 
▪ “(D) an amino acid; 
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▪ “(E) a dietary substance for use by man to supplement the diet by 
increasing the total dietary intake; or 
▪ “(F) a concentrate, metabolite, constituent, extract, or combination 
of any ingredient described in clause (A), (B), (C), (D), or (E)” 
(FDA, 1994) 
This act requires that all substances adhering to the definition of the dietary or herbal 
supplement must comply with some regulations. For example, the FDA prohibits 
distribution of adulterated or misbranded products and manufacturers must comply with 
the Current Good Manufacturing Practices as defined by the FDA (Curry, Schaffer, & 
Yoon, 2016).  
However, under these conditions, these substances are automatically placed in 
their own category, removing them from the regulations imposed on pharmaceutical 
drugs. In fact, this act mandates that dietary supplement regulation mirrors that of a 
specialized food group rather than a drug. By placing dietary and herbal supplements 
under the broad umbrella of food regulation, these substances are excluded from the 
stringent requirements that govern pharmaceutical drugs. The most prominent exclusion 
revolves around the notion of premarket approval and pre-clinical data and trials. 
Pharmaceutical drugs, before even approaching distribution in the market, are required to 
provide sufficient data on the effectiveness and the potential side effects of the product to 
gain premarket approval by the FDA. A significant amount of research and thorough 
clinical trials predate the release of any modern drug. In contrast, the DSHEA dictates 
that manufacturers are responsible for determining the safety of the product and its claims 
(Spies, 2006). Thus, the burden lies with the FDA to provide proof that a dietary or 
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herbal supplement poses significant harm before the substance can be removed from the 
market.  
The DSHEA also allows dietary supplements to make certain nutritional support 
claims. Taken from the FDA:  
 “(A) the statement claims a benefit related to a classical nutrient 
deficiency disease and discloses the prevalence of such disease in the 
United States, describes the role of a nutrient or dietary ingredient 
intended to affect the structure or function in humans, characterizes the 
documented mechanism by which a nutrient or dietary ingredient acts to 
maintain such structure or function, or describes general well-being from 
consumption of a nutrient or dietary ingredient (FDA, 1994).  
In other words, under this section of the DSHEA, there are four main claims that dietary 
supplements can make without causing the FDA to consider the product as a drug. To 
make these claims, the seller must provide data supporting the claims and to ensure that 
these claims contain no false or misleading information. The FDA also requires all 
dietary and herbal supplement labels to bear the disclaimer, “This statement has not been 
evaluated by the Food and Drug Administration. This product is not intended to diagnose, 
treat, cure, or prevent any disease” (FDA, 1994; Spies, 2006). Despite the disclaimer, this 
section gives dietary supplements a looser leash, allowing them to publish certain types 
of claims that regimented drugs are prohibited from making. For example, a seller can 
claim that cranberry supplements can increase the acidity of urine to improve urinary 
tract function, but they cannot claim that these supplements decrease the likelihood of 
urinary tract infections, nor can they claim that these supplements prevent an individual 
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from contracting a UTI. By changing the wording of the claim, herbal and dietary 
supplements can publish and market certain nutritional support claims without adhering 
to the governing factors of traditional drugs (Spies, 2006).  
Criticisms of DSHEA: Biochemical Impact of Active Ingredients and Potential Side 
Effects  
Despite their seemingly benign reputation, herbal supplements rely on active 
chemical compounds extracted from plants to induce physiological changes in the body, 
which mimics the mechanism that drugs employ. Especially in the presence of certain 
active compounds in pharmaceutical drugs, herbal products can have pharmacodynamic 
interactions that result in adverse side effects. Thus, herbal medications can also pose a 
significant health risk, in the right conditions and should be regulated as such. While the 
current policies in place keep the price of herbal medications significantly lower 
compared to conventional drugs, the almost hands-off approach significantly increases 
risk towards the consumers due to poorly defined and manufacturing processes. Many 
herbal compounds have been proven to have pharmacodynamic interactions with the 
active components in commonly used conventional drugs. For example, St. John’s Wort, 
an herbaceous perennial plant commonly used for the treatment of depression, has been 
proven to interact with a number of drugs, including immunosuppressants, 
contraceptives, anticoagulants and more. St. John’s Wort has been found to significantly 
reduce the pharmacological effect of warfarin when taken in combination. While many of 
these herb-drug interactions exist, poor regulation and research behind these adverse side 
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effects hinder the scientific process in gathering accurate data and implementing the 
appropriate response to minimize consumer risk.   
While the FDA seems to be the hallmark for conventional drug regulation, its 
approach to herbal medication leaves the door open to many different loopholes that 
might increase the health risk for many consumers. Based on the analysis of the DSHEA, 
the main regulatory policy enforced by the US, herbal supplements receive more lax 
regulations compared to their drug counterparts. Without rigorous screening and strict 
manufacturing restrictions, herbal medication manufacturers require less testing and the 
overall process from development to distribution remains less regulated. As a result, 
many of the herbal supplements and medications on the market may pose a significant 
health risk towards consumers as the quality of the ingredients that many sellers claim to 
be present are not properly accessed. In fact, a study conducted by researchers in Toronto 
analyzing the ingredients contained in 44 different herbal supplements sold in the United 
States and Canada revealed that less than half of these supplements contained any herbal 
substances disclosed on the label and more than half of these substances contained 
ingredients not disclosed on the label (Alostad et al., 2018). The fact that many herbal 
medications currently on the market contain undocumented materials poses a significant 
risk for consumers, especially if that ingredient can cause an allergic reaction or other 
adverse side effects or if that material is of poor quality.  
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The DSHEA along with all other FDA regulation policies allows manufacturers 
and sellers to use fillers or substitutions in their products, which once again, constitutes 
not only as food fraud but also poses health issues for consumers. Current analytical and 
quantification techniques fail to identify all the active ingredients in most herbal 
supplements, partly due to the combination of organic chemicals that many of these 
products contain. Even with standard chemical practices used by all manufacturers for 
analyzing the number of active ingredients in the supplement, there is still not enough 
information to discern whether these active components exhibit an adverse side effect 
(Newmaster, Grguric, Shanmughanandhan, Ramalingam, & Ragupathy, 2013). In 
comparison to many other countries, who require herbal supplements to pass pre-market 
approval, the current U.S. regulatory system, when it comes to herbal medicine, is 
severely lacking. Rather than a preventative approach, the FDA allows unproven 
supplements to enter the market and directly reach consumers.  
The current regulation system puts consumers at risk because these policies 
seemingly downplay the potential effects of herbal medications; rather, the regulation 
should reflect the potential risk posed by consumption of these products. Currently, the 
FDA encourages voluntary recall of the supplements they find adulterated or 
contaminated. In 2018, the FDA issued its first mandatory recall for herbal products 
containing kratom, an herb that has psychotropic effects, produced by the manufacturer 
Triangle Pharmanaturals LLC (FDA, 2018). However, this only affects a small number of 
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supplements on the market. Taking a preventative approach, these products should have 
to undergo pre-market approval and at the very least, provide data that demonstrates its 
safety in consumption. The burden of proof, therefore, shouldn’t lie with the FDA, but 
manufacturers and sellers alike should play an active role in elucidating the efficacy, 
safety, and quality of their products.  
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Chapter 3.1: The complexity of Pharmaceutical Drugs and Herbal Supplement Use 
During Pregnancy 
 
Pregnancy is marked by large changes to both the maternal physiology and 
environmental changes. On top of navigating numerous prenatal visits, scans, and tests, 
women must also rethink their medication regiment. The FDA has established a 
categorical system to delineate the safety of different medications during pregnancy, 
which can be summarized in  
 
 
 
 
Table 1. This system allows healthcare providers to identify which medications to 
recommend or prescribe, considering the associated side effects. Only a small number of 
herbal supplements have been categorized using this system. The development of the 
fetus and hormonal changes during all three trimesters of pregnancy alters the effect of 
many different drugs. This complicates the trajectory of care. To better understand the 
hazards of medications on both the development of the fetus and the maternal system, we 
will first look at the multitude of hormonal changes that occurs during each trimester of 
pregnancy. These fluctuations cause many of the symptoms experienced, and hence, 
opens the door to treatment by pharmacological and/or herbal therapies. We will then 
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compare the pharmacological therapies with the herbal remedies, looking specifically at 
the mechanism of action, the side effects, and the potential interactions with other 
substances.  
 
 
 
 
 
Table 1: FDA pregnancy risk categories for different medications with examples of drugs that fall 
into each category. Information obtained from Survey, J. & Chang, J. (2014). Over-the-counter 
medications in pregnancy. American Family Physician, 90(8), 548-555. 
https://doi.org/10.1016/j.acthis.2015.01.004 
Category 
 
Description Examples 
Category A  Adequate and well-controlled studies 
have failed to demonstrate a risk to the 
fetus in all trimesters  
 
Category B Animal reproduction studies have 
failed to demonstrate a risk to the fetus  
There are no well-controlled studies in 
pregnant women  
Acetaminophen 
Benadryl  
 
Category C  Animal reproduction studies have 
shown adverse effects on the fetus  
There are no well-controlled studies in 
humans  
Potential benefits may warrant the use 
of the drug during pregnancy  
Guaifenesin (Humibid L.A.) 
Miconazole (Monistat)  
Calcium Carbonate (Tums)  
Category D There is evidence of human fetal risk 
based on adverse reaction data from 
studies in humans  
Aspirin (in the third trimester) 
Ibuprofen (in the third 
trimester) 
Category X Studies in animals or humans have 
demonstrated fetal abnormalities  
The risks involved clearly outweigh 
the potential benefits  
Castor oil  
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Changes in Maternal Hormones and Metabolism 
 
 To successfully develop a zygote, a fertilized egg, into an infant requires complete 
rewiring of maternal metabolism. Throughout the approximately 280 days of a normal 
human pregnancy, changing biochemical parameters dictate a whole orchestra of 
physiological changes to support a pregnancy. Steroid hormones, peptide hormones, and 
prostaglandins help to establish a protective environment for fetal growth and develop a 
system for the transportation of nutrients between maternal and fetal systems (Lockitch, 
1997). Disruptions to the normal function of these interactions may cause serious side 
effects in both the fetus and the mother. Thus, pregnancy presents an interesting dilemma 
in terms of the use of medicines and alternative medicines. Side effects and the molecular 
influence of both pharmaceutical drugs and herbal medications should be stringently 
documented and researched to prevent adverse interactions and side effects.    
 The four main hormones that govern pregnancy are estrogen, progesterone, 
human placental lactogen (hPL), and human chorionic gonadotropin hormone (hCG). 
These hormones are synthesized by the placenta throughout most of the pregnancy and 
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rely on the metabolic relationship between the maternal and fetal systems. The patterns of 
estrogen, progesterone, and hCG can be summarized in Figure 2. It should be noted that 
estrogens, progesterone, and hLP follow a similar pattern with lower levels during the 
beginning of the pregnancy before gradually increasing and peaking near term 
(Blackburn, 2007).  
 
 
Figure 2: Graph depicting patterns of estrogen, hCG, and progesterone levels during 
pregnancy from fertilization to labor. Figure adapted from Guyton, A.C (1987). Human 
Physiology and mechanisms of disease (4th ed.). Philadelphia: Saunders. 
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In the weeks following conception, hCG levels can be detected in the blood in 7 
days after ovulation, and substantially increases until concentrations in the maternal 
serum peaks at around 8 and 12 weeks before slowly declining. The sudden rise in hCG 
extends the functionality of the corpus luteum (CL), a structure that allows for the 
production of progesterone, into a couple of weeks allowing the body to sustain the 
pregnancy until the placenta takes over. Moreover, studies indicate that hCG may play a 
role in the implantation of the embryo to the uterine wall. Receptors on the endometrium 
(the uterine lining) promote the secretion of relaxin and progesterone by the CL, which 
stimulates the physiological changes required in early pregnancy. Abnormalities in the 
expression of hCG receptors and abnormal levels of the hormones itself can be associated 
with issues in female reproduction and pregnancy (Keay et.al., 2004; Lockitch, 1997).  
  With hCG maintaining the functionality of the corpus luteum, levels of 
progesterone, a steroid hormone in the maternal serum remains elevated. Under the 
influence of hCG, progesterone is produced by the CL until its production is sustained by 
the placenta 6-8 weeks after fertilization. Progesterone combats the labor-inducing effects 
of other hormones such as estrogen, prostaglandins, and oxytocin, allowing for the 
pregnancy to sustain. In addition to preventing menstruation, which would shed the 
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uterine lining needed for implantation of the ovum, progesterone, a pro-gestational 
hormone, maintains pregnancy by promoting uterine quiescence. The myometrium, the 
smooth muscle of the uterus, plays a large role in the duration of pregnancies and in the 
birthing process. Through most of the pregnancy, the myometrium remains in a relaxed 
state, stretching to accommodate the growing fetus mainly sustained by the presence of 
progesterone. At the time of birth, rhythmic contractions of the myometrium allow for the 
expulsion of the fetus and placenta. After 8 weeks of pregnancy, the main production of 
progesterone shifts from the CL to the placenta and placental trophoblasts, where the 
levels of progesterone remain elevated until the placenta is lost following parturition. 
Interestingly, disruption in the production of progesterone initiates labor by stimulating 
uterine contractions. Clinical studies indicate that progesterone supplement may decrease 
preterm labor in women with high risk for preterm labor, however, more research is 
needed before this treatment can be applied clinically (Mesiano et.al., 2011; Tuckey, 
2005). Progesterone also serves as a substrate for the production of corticosteroids by the 
fetal adrenal gland. Due to insufficient levels of enzymes required to form several 
different corticosteroids, the fetus is unable to use the main metabolic pathway to form 
these components. Thus, they rely on progesterone produced by the placenta using 
precursors from the maternal system to form mineralocorticoids and corticosteroids, 
which are hormones that hold physiological importance (Blackburn, 2007).  
 Estrogen exists within the body in three major forms: estrone, estradiol, and 
estriol. During pregnancy, levels of all three major estrogens substantially increase. 
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Notably, levels of estradiol production increase almost 1000 times baseline levels by the 
third trimester of the pregnancy. Estrogen, like hCG and progesterone, is mainly 
produced by the placenta, however, unlike progesterone, 90% of the precursors are 
derived from the fetus instead of the maternal system. Furthermore, while progesterone 
decreases myometrial activity and promotes myometrial constriction, estrogen provides 
the opposite effect – enhancing myometrial activity and promoting myometrial 
vasodilation. In addition to effects on the uterine wall, estrogen derivatives also increase 
maternal sensitivity to carbon dioxide and secretion of other hormones such as prolactin 
and serum binding proteins (Blackburn, 2007).  
 Another key component in developing the environment to sustain a pregnancy 
revolves around changing maternal metabolism to support the development of fetal 
metabolism, as task mediated by the hormone hPL. Almost exclusively secreted by the 
placenta into the maternal circulation, hPL is hypothesized to be responsible for the rise 
in maternal plasma insulin-like growth factor (IGF-1). During early pregnancy, hPL and 
other placental hormones drive an increased appetite and food intake as well as energy 
storage leading to an increase in the deposition of fat reserves. As the pregnancy 
progresses towards term, hPL mobilizes these reserves to support fetal growth (Magon & 
Kumar, 2012).  
Use of Medicine During Pregnancy: An Upward Trend   
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 With a whole slew of changes occurring, pregnant women often experience a 
whole array of different symptoms, ranging from emesis to constipation to fatigue. 
Because of the complex physiological changes coupled with dynamic shifts in hormones 
and metabolic homeostasis, the use of medication to address symptoms in pregnancy 
proves to be difficult for providers to navigate. Providers must balance not only the 
effects of these medications on the mother but also an unintended subject, the fetus. 
Perhaps one of the biggest medical disasters revolves around the severe birth defects 
affecting over 10,000 children globally from 1957 to 1962. At the center of this tragedy 
lies Thalidomide, a drug prescribed to women to treat morning sickness. Administration 
of this drug caused severe birth defects including limb development and significant organ 
tissue damage in infants worldwide (Ghoreishi, 2014). The thalidomide crisis greatly 
impacted the dynamic of medication use during pregnancy.  
For the past several decades, the use of both over the counter medications as well 
as prescription medicine during pregnancy shows a substantial increase. As depicted by 
the figure below, in 2008, 93.9% of women reported taking at least one medication 
anytime during the pregnancy, a substantial increase from around 50% in 1967-1981. 
Moreover, this figure also supports the notion that the average number of medications 
taken follows a similar upward trend, from an average of 2.5 drugs in 1976 to over 4 in 
2008. The number of women taking four or more medications also increased, from 23.3% 
in the late 1970s to 50.1% in 2008. Interestingly, this trend continues into the current day 
(Mitchell et al., 2011). In a 2018 study, out of 9,546 women surveyed, 95.7% took 
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medication during the first trimester with 30.5% meet the requirements for 
polypharmacy, defined as taking five or more medications. Excluding vitamins and 
herbal supplements, 74.4% of women took at least one medication during pregnancy 
(Haas et al., 2018; Lee et al., 2006).  \ 
 
 
Figure 3. Average medication uses during pregnancy and the first trimester. The chart 
shows an upward trend in medication usage throughout the duration of pregnancy. 
Figure adapted from Mitchell, A. A., Gilboa, S. M., Werler, M. M., Kelley, K. E., Louik, 
C., & Hernandez-Diaz, S.. (2011). Medication use during pregnancy, with particular 
focus on prescription drugs: 1976-2008. American journal of Obstetrics and Gynecology, 
205(1), 51.e1-51.e8. http://doi.org/10.1016/j.ajog.2011.02.029.  
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Drug safety thus remains a major priority for both researchers and providers. 
Since the thalidomide crisis, many pharmaceutical drugs have been classified as 
teratogens, a substance that can cause malformations in a developing embryo. Warfarin, 
an anticoagulant medication, valproic acid, an anticonvulsant, and isotretinoin, an acne 
medication serves as examples of teratogens. As a result, many of these pharmaceutical 
drugs are strictly modulated and monitored by pharmacists and healthcare workers.  
However, the regulation of over the counter medications (OTC) use poses a difficult task, 
relying mostly on patient disclosure. While the prevalence of OTC and their easy 
accessibility suggests usage safety by nonpregnancy populations, this doesn’t extend to 
safety during pregnancy (Servey & Chang, 2014). Little to no data exists detailing the 
long-term effects of most OTC medications. Thus, given their prevalence in routine 
obstetric care, stringent research on the potential side effects and interactions should be 
conducted to ensure the safety of both the mother and the fetus.  
 The upward trend in medication use during pregnancy also extends to herbal 
supplement use during pregnancy. In fact, a vast range between 7% to 55% of expectant 
mothers globally reported using herbal remedies or other types of natural health products 
during pregnancy and lactation (Facchinetti et.al., 2015; Yusof et.al., 2016). Prevalence 
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of usage is dependent on geography as well as demographics. According to various 
studies, the top four herbal medicines used by pregnant women globally are ginger to 
treat nausea, valerian to aid with insomnia, and raspberry to induce labor (Abebe, 2002; 
Holst et.al., 2011; Kennedy et.al., 2013).  
 
 
 
 
 
 
 
 
 
 
 
Table 2 provides a summary of several herbal supplements commonly used during 
the first three trimesters of pregnancy with their intended benefits, the risks associated 
with usage, and documented interactions with other medications. Like OTC medications, 
the regulation of complementary and alternative medicine proves a difficult task. Without 
a prescription requirement, these substances can be readily purchased at different stores 
and sources without stringent quality control by the FDA. Moreover, often, women 
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neglect to inform their midwife or physician about herbal medicine use, increasing the 
chances of herb-drug interactions during pregnancy (Hall et.al., 2011; Kennedy et al., 
2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Common herbal supplements used by women during pregnancy.1 (Abebe, 2002), (Tiran, 
2012); 2 (Holst et al., 2011); 3 (Abebe, 2002) 4 (Holst, Haavik, & Nordeng, 2009); 5 (Dugoua, 
2010), (Dugoua, Seely, Perri, Mills, & Koren, 2008); 6 (Dugoua, Jean-Jacques; Mills, Edward; 
Perri, Daniel; Koren, 2006); 7 (Newmaster et al., 2013) 
Herbal 
Supplement  
Reason for use  Benefits  Associated risks  Interactions  
Ginger 1 
 
To treat 
morning 
sickness, cold 
and flu-like 
symptoms, 
Diaphoretic 
properties  
 Stomach irritant, 
Heartburn 
Anticoagulant 
effects that 
might interfere 
with 
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gastrointestinal 
diseases  
No reported 
increase in birth 
malformities  
 
 
 
 
anticoagulant 
drugs 
Cranberry 2  
 
 
 
To treat UTIs, 
colds, water 
retention  
Research 
shows 
questionable 
efficacy in 
preventing 
recurrent UTI 
in pregnancy 
 
 
No significant 
side-effects 
reported  
 
Valerian 3 
 
 
 
To treat 
insomnia and 
restlessness  
Induce mild 
sedation and 
hypnosis  
No reported risk 
to the fetus 
Can potentiate 
the sedative 
effects of other 
central 
nervous 
system drugs 
Valerian 
withdrawal 
mimics 
withdrawal of 
ben 
Benzodiazepines 
 
 
 
 
Raspberry Leaf 4 
 
 
 
Flu and cold 
symptoms, to 
prime the uterus 
for labor, 
stimulate labor  
Research 
shows 
contradictory 
results for the 
efficacy; the 
active 
component 
remains 
unidentified  
None 
documented  
No evidence of 
fetal malformities  
 
 
 
 
 
 
 
Blue Cohosh 5 
 
To prepare for 
labor  
Evidence of 
initiating 
Several cases of 
in vivo evidence 
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uterine 
contractions  
of teratogenic, 
embryotoxic, and 
oxytocic effects   
Ginkgo 6 
 
 
 
To use for 
premenstrual 
syndrome 
(PMS)  
Strong 
evidence for 
therapeutic use 
for 
intermittent 
claudication, 
dementia, 
altitude 
sickness, and 
vertigo  
The antiplatelet 
activity could 
prolong bleeding 
during delivery  
 
May potentiate 
anti-clotting 
effects of 
anticoagulant 
medications  
No risk 
associated with 
consumption 
during lactation 
 
 
 
Senna7  
 
 
 
 
To treat 
constipation  
Evidence of 
laxative 
effects   
Prolonged use 
can cause chronic 
diarrhea, liver 
damage, 
abdominal pain 
(Sennosides) 
Interact with 
immune cells 
in the colon  
 
Dangers of Medication Use During Pregnancy  
 
 As mentioned, drug use during pregnancy poses an imminent challenge to the 
current healthcare system. A portion of this issue is attributed to holes in clinical practice 
and FDA regulation, but another compounding factor comes from the changes in 
maternal drug metabolism. Expanding on the hormonal changes, pregnancy is also 
hallmarked by distinct physiological changes including a significant increase in a plasma 
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volume expansion of erythrocyte mass, altered distribution of cardiac output, and an 
increase in plasma protein synthesis (Lockitch, 1997).  
 
Table 3 shows changes in absorption, distribution, metabolism, and excretion that occurs 
during pregnancy. Alterations in the maternal system change the way drugs and 
supplements are metabolized, thus changing the effect and potency of many drugs. For 
example, an increase in renal blood flow and pulmonary function during pregnancy may 
decrease the effectiveness of medications, due to the increase in excretion efficiency. Due 
to large metabolic changes and hormonal changes, prescribing drugs during pregnancy 
remains a difficult task for healthcare providers. They must consider a multitude of 
changes and factors to ensure the safety for the mother as well as the fetus while also 
treating various symptoms that arise during pregnancy.  
 
 
 
Table 3: Changes to factors that influence metabolism of drugs during pregnancy. 
Adapted from Reed, MD * Blumer, J.L. (2006). Pharmacologic treatment of the fetus. In 
R.J. Martin, A.A. Fanaroff & M.C. Walsh (Eds.). Fanaroff and Martin’sneonatal-
perinatal medicine: Diseases of the fetus and infant (8th ed.), Philadelphia: Saunders 
Influence of Pregnancy on Physiological Aspects of Drug Disposition 
Pharmacokinetic Parameter  Change in Pregnancy  
Absorption 
Gastric emptying 
Intestinal Motility  
 
Increased  
Decreased  
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Cardiac Output  
 
Increased  
Distribution 
Plasma Volume  
Total body water  
Plasma proteins  
Body fat  
 
Increased  
Increased  
Decreased  
Increased  
 
Metabolism 
Hepatic  
Extrahepatic  
Plasma proteins  
 
Increased or Decreased  
Increased or Decreased  
Decreased  
 
Excretion 
Renal blood flow  
Pulmonary function  
 
Increased  
Increased 
  
.  
 
 
 
 
Chapter 3.2: Treating Symptoms During Pregnancy: A Look at Common 
Pharmacological and Herbal Options 
 
Morning Sickness: An Imbalance of hCG 
 
 Nausea and vomiting or emesis are some of the most common symptoms 
experienced by expectant mothers with nausea affecting 75% of pregnant women and 
emesis occurring in 50% of pregnant women. In a small number of patients, hyperemesis 
gravidarum, a condition characterized by persistent vomiting leading to dehydration and 
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weight loss, may develop. Typically manifesting in the early weeks of the first trimester 
and peaking at around 9 weeks of gestation, most instances resolve by the end of the first 
trimester. The severity of nausea and vomiting of pregnancy (NVP) can range from mild 
to unbearable instances, lasting throughout the day, contrary to the public term of 
morning sickness (M.L., S.M., & J.A., 2006; Niebyl, 2010). Interestingly, the clinical 
course for NVP correlates with the levels of hCG. In theory, an increase in hCG, 
especially during pregnancy, may stimulate the production of estrogen, a hormone known 
to increase instances of nausea and emesis (Niebyl, 2010). The vomiting center, when 
activated, mobilizes motor neurons that descend down the cranial nerves to the upper 
gastrointestinal tract before reaching the vagal nerve, a cranial nerve controlling the 
digestive tract. The activation of this center causes the contraction of the abdominal 
muscles and the diagram, initiating the action of vomiting. Irritants are known to activate 
this center. In addition, the presence of certain hormones and neurotransmitters might 
trigger this center (Becker, D.E., 2010). 
An Overview of Treatments for NVP 
 
 Clinically, multiple methods can be used to alleviate NVP and improve the 
quality of life for expectant mothers. Broken into two general groups, providers may 
employ a pharmacological approach or a nonpharmacological approach, each treatment 
containing a different set of benefits and disadvantages. The first approach to NVP 
treatment generally involves behavioral and environmental changes. While the efficacy 
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of this approach remains unproven, women are often encouraged to shift their diet – 
consuming smaller meals and avoid spicy foods. In addition, providers might encourage 
women to take their prenatal vitamins at night and suspend iron therapy (M.L. et al., 
2006).   
 The use of herbal medicine also falls within the category of nonpharmacological 
approaches. The most common herbal supplement used to treat nausea is ginger (Zingiber 
officinale). Widely used as a spice to enhance the flavor of food, ginger is among the top 
20 selling herbal supplement in the United States. Various preparations of ginger exist, 
including extract in teas, capsules, or root powder. Due to a lack in federal oversight, the 
dosages present in these different preparations and brands may vary greatly – from 250 
mg to 1000 mg (Borrelli et.al., 2005; Ebrahimi et.al., 2010).  While the mechanism 
employed by ginger has not been fully elucidated, the antiemetic effects are attributed to 
gingerol. Other components such as galanolactone are thought to act as serotonin and 
vasopressin antagonists to decrease tachygastric activity especially in the ileum, a portion 
of the small intestine. Interestingly, some prescription anti-emetics employ the same 
mechanism (Tiran, 2012). Multiple studies indicate that ginger is effective in reducing the 
severity of NVP (Borrelli et al., 2005; M.L. et al., 2006; Ozgoli et.al., 2009; Westfall, 
2004).  
 If symptoms persist or worsen, providers turn towards pharmacological therapies. 
A number of different drug categories can be considered to manage nausea and vomiting 
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during pregnancy. Antihistamines, such as meclizine and diphenhydramine (Benadryl ®), 
directly inhibit the action of a histamine receptor, thus indirectly decreasing the 
stimulation of the vomiting region. The effectiveness of antihistamines has been proven 
over a series of tests conducted in the 1960s. Another class of drugs typically used to 
treat NVP is dopamine antagonists (Metoclopramide), serotonin antagonists 
(Ondansetron), and cholinergic antagonists (dicyclomine and scopolamine). These 
antagonists block certain receptors in the vomiting center or certain digestive sites to 
decrease stimulation or triggers that might activate these areas (Becker, D.E., 2010).  
Risks/Interactions Associated with Nonpharmacological Methods  
 
   Despite limited research, many clinical studies indicate that ginger proves to be 
an effective and safe method to manage NVP. However, limited data exists on the 
appropriate dosage of ginger to achieve optimal results. One study indicates that a daily 
dose of 1000 mg, in the form of a capsule achieves a reduction in the intensity of nausea 
and vomiting in women (Ozgoli et al., 2009). Generally, a dosage of 1000 mg or less per 
day is deemed safe. Multiple randomized controlled trial studies show a reduction in 
symptoms with infrequent side effects overall (Ebrahimi et al., 2010). There is still a lack 
of studies detailing the effects of extended use of these supplements on the mother and 
the fetus. Moreover, as mentioned before, due to a lack of FDA regulation, each 
preparation of ginger may contain different amounts of active ingredients, thereby 
altering the effectiveness of the treatment. Additionally, minimal federal oversight into 
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the quality and manufacturing of herbal medicines, including ginger, leaves the door open 
of adulterations.  
 The use of ginger may result in a multitude of symptoms, many due to 
interactions with other medications. Recently, several studies indicate that ginger 
contains anticoagulant effects. When taken in tandem with other anticoagulant therapies 
such as Warfarin or aspirin, the effects of these drugs can substantially increase. Thus, 
women with a past medical history of vaginal bleeding or clotting disorders are 
encouraged to avoid taking ginger during their pregnancy. In addition to interactions with 
anticoagulants, ginger also shows potential to interact with other classes of drugs such as 
benzodiazepines, beta blockers, barbiturates, and other herbal medications (Tiran, 2003).   
 As one of the most popular and studied herbal supplement, the use of ginger in 
primary care and in pregnancy seems to be a safe and inexpensive option. However, 
despite promising research, the lack of regulation in purity coupled with lenient dosage 
management by the FDA should raise concerns. Ginger can exacerbate the effects of 
anticoagulants and interact with other drugs. Due to the tendency of patients to exclude 
the use of herbal supplements from healthcare providers, the risk of herb-drug 
interactions substantially increases. While generally safe to use during pregnancy, 
caretakers should monitor ginger and other herbal supplements similar to the way to 
manage pharmaceutical drugs.  
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Risks/Interactions Associated with Pharmacological Methods  
 
Compared to their herbal medicine counterparts, the pharmacological methods are 
better researched in terms of their exact mechanism, teratogenic effects, and safety. 
Multiple studies on the safety and effectiveness of dopamine, serotonin, and cholinergic 
antagonists indicate almost no teratogenic effects or adverse side effects for the mothers 
(Ebrahimi et al., 2010; M.L. et al., 2006; Niebyl, 2010). 
 Biochemical Changes Associated with Sleep Disturbances in Pregnancy   
 
 Another common symptom reported by 66% to 94% of pregnant women reports 
sleep disturbances, including insomnia. Due to marked mechanical changes coupled with 
hormonal fluctuations, the quality and length of sleep change profoundly. Ailments such 
as lower back pain, leg pain, and abdominal discomfort affect the architecture of sleep. 
Pregnant women tend to have increased light sleep (stage 1 sleep) and suppression of 
REM or deep sleep. Importantly,  as seen in  
 
Figure 4, the marked elevation of progesterone and estrogen due to pregnancy plays a 
large role in changing the quality of sleep. Estrogen decreases REM sleep as well as 
increase upper airway resistance by causing swelling. The increased difficulty breathing 
might play a role in sleep disruption. Progesterone, on the other hand, increases non-
REM sleep. Similar to the effect of estrogen on the airway, progesterone increases 
ventilation and respiratory alkalosis, leading to instability in the airways and disruption in 
sleep. Furthermore, because progesterone shares binding sites on corticosteroid binding 
globulin, an increase in progesterone level directly correlates to an increase in free 
cortisol. This disturbance in the cortisol-melatonin ratio is hypothesized as a cause of 
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sleep disturbances and insomnia (Kizilirmak et. al., 2012; Reichner, 2015; Sharma et. al., 
2004).  
 Interestingly, the typical sleeping pattern of expectant mothers’ changes and shifts 
throughout the trimesters. During the first trimester, the rise in progesterone may cause 
daytime sleepiness. However, even though there is a meaningful increase in sleep 
duration, the efficiency and quality of sleep remain depressed, thus, common complaints 
during this period may also include fatigue. In the second and third trimesters, the total 
night-time sleep duration falls, resulting in an increase in non-REM sleep and a reduction 
of REM sleep. Nocturnal disturbances become increasingly common. Some women can 
develop insomnia or difficulty falling asleep (AM, SK, SK, & IS, 2016; Pien & Schwab, 
2004; Sharma et al., 2004).  
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Figure 4: Impact of different hormones on the quality of sleep in pregnancy. Figure adapted 
from Guyton, A.C (1987). Human Physiology and mechanisms of disease (4th ed.). 
Philadelphia: Saunders. 
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Overview of Treatments for Insomnia During Pregnancy  
 
 Similar to the treatment for NVP, sleep disruptions can be mediated by 
nonpharmacological methods and pharmacological therapies. Nonpharmacologic 
interventions include sleep hygiene and sleep education as well as behavioral therapy. 
Changing the surrounding environmental factors by avoiding certain foods, dimming the 
lights, and changing sleeping position may help promote a restful night of sleep. A step 
above sleep hygiene and education involves behavioral therapies that promote relaxation, 
employ sleep restriction, and decrease anxiety and stimulus through cognitive therapy 
(AM et al., 2016). Another major alternative or nonpharmacological therapy utilizes 
herbal supplements to promote sleep. Valerian (Valeriana officinalis) is an herb 
commonly recognized for its sedative effect often available in many different 
preparations including extracts, infusions, and tinctures. With a mixture of active 
ingredients, the main mechanism of valerian is attributed to valerenic acid and 
sesquiterpenes. By inhibiting the breakdown of the enzyme charged with the degradation 
of GABA, valerian causes a decrease in activity in the central nervous system resulting in 
a sedative effect (Abebe, 2002; Houghton, 1998).  
 If insomnia persists, a limited number of pharmacological therapies may be 
considered for short-term use. Most sedative-hypnotics remains unsafe for use during 
pregnancy, however, diphenhydramine (Benadryl) or zolpidem (Ambien) when used 
infrequently are currently considered safe for the mother and the fetus. Similar to the 
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proposed mechanism for valerian, zolpidem acts on GABA receptors to induce sedation 
(Doble, 1996). The medical community still remains divided on the use of Zolpidem 
during pregnancy due to uncertainty about dosage and potential side effects. 
Diphenhydramine, a known histamine receptor antagonist, induces sedation by altering 
the regulation of the sleep-wakefulness continuum (Turner, Handford, & Nicholson, 
2006). Insomnia remains a difficult disorder to treat, and stringent drug management is 
imperative in preventing adverse side effects.  
Risks/interactions Associated with Nonpharmacological Therapies  
 
 Only a handful of clinical trials and experiments have been conducted on the 
effectiveness and safety of valerian. Both clinical and animal studies can have sleep-
inducing and tranquilizing effects in-vivo. With a mixture of different constituents, 
valerian utilizes several different mechanisms to cause a tranquilizing or sedative effect. 
However, the activity of valerian is dependent on the concentration of its constituents. 
Due to a variety of different preparations, the effectiveness of this herbal supplement 
greatly varies from company to company. With current FDA regulations, no formal 
standardization for the preparation of valerian currently exists, which raises concerns 
about safety.  
 Limited research exists studying the pharmacokinetic and pharmacodynamic 
interactions between valerian and other herbal medications or pharmaceutical drugs. Due 
to its effect on GABA, interactions with barbiturates and opioids are plausible. Valerian 
 
 
51 
 
may exert an additive or antagonistic effect in response to tranquilizers, other sedative 
medications, and opioids. In addition, some studies indicate that valerian potentially 
reduces the effect of antidepressants when taken in tandem. In vitro evidence also 
suggests that valerian might inhibit CYP, opening the door for potential interactions with 
CYP substrates such as warfarin and atorvastatin. (Abebe, 2002; Cramer et.al., 2006; 
Houghton, 1998).  
Risks/Interactions Associated with Pharmacological Therapies  
 
 In general, pharmacological treatments for insomnia and sleep difficulty during 
pregnancy should be short-term. Most sedatives may be teratogenic, posing a significant 
risk towards the fetus. Currently, no official pharmacological therapy for insomnia is 
classified as safe during pregnancy.  Zolpidem has been shown to increase symptoms of 
depression when combined with central nervous system acting drugs such as Tramadol 
and Alprazolam. This indicates that Zolpidem might influence the metabolism and hence 
the function of other medications. Due to its interactions with GABA receptors in the 
brain, potent interactions between Zolpidem and illicit drugs that interact with the central 
nervous system may cause catastrophic side effects. Other categories of sedative 
pharmaceutical therapies also pose a major risk to the fetus, such as drug withdrawal 
symptoms following birth (Jazbar et. al., 2018).   
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Chapter 3.3: Induction of Labor: A Review of Pharmacological and Herbal 
Methods 
 
Induction of Labor: Biochemical changes  
 
 The initiation and development of a pregnancy, as discussed earlier, relies on a 
whole orchestra of hormones and molecules. Similarly, the initiation and stimulation of 
labor are greatly dependent on several major proteins: progesterone, prostaglandins, 
interleukin-8, and oxytocin receptors. As mentioned above, progesterone levels remain 
high during pregnancy to combat labor-inducing effects. This steroid hormone inhibits 
the ripening of the cervix, governed by another hormone, as well as combat the effects of 
labor promoting hormones. While there is no noticeable progesterone withdrawal during 
human pregnancy, some studies indicate that progesterone might undergo a “functional” 
withdrawal. Speculation into the role of progesterone during labor remains debated and 
postulated. Another important hormone in inducing labor is prostaglandins, which 
stimulate myometrial contractility and cervix ripening. Changes in the synthesis and the 
metabolism of prostaglandins fluxes over the duration of the pregnancy and plays a role 
in governing the labor process. Up-regulation of prostaglandins near the end of 
pregnancy stimulates contractions during labor. The hormone interleukin-8 is produced 
by the endometrium, myometrium, decidual cells, and the placenta. The expression of 
this hormone correlates with increasing gestational age, suggesting that interleukin-8 
might play a role in ripening the cervix prior to cervical dilation. The final key player in 
the induction of labor in humans is the oxytocin receptors. Increased sensitivity to 
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oxytocin in the myometrium plays a large role in promoting uterine contractions, thus, 
biochemical changes both the levels of oxytocin and the affinity of oxytocin receptors to 
their substrate largely contributes to the induction of labor (Mohan et. al., 2004). Figure 4 
shows a summary of the regulators involved in labor induction. This figure also shows 
that other secondary factors such as nitric oxide and ion channels, while not discussed 
thoroughly in this paper, also plays a major role in the induction and sustaining labor.  
 
 
 
 
 
 
 
 
 
 
 
54 
 
 
 
Figure 5:  The relationship of major hormones and regulators in relation to uterine 
contractility and parturition. CRH, corticotropin-releasing hormone; NO, nitric oxide; 
PGI2, prostacyclin, PTHrP, parathyroid hormone-related peptide. Adapted from Challis, 
J.R.G. (1999). Characteristics of parturition. In R.K. Creasy & R. Resnik (eds.). 
Maternal-fetal medicine (4th ed.). Philadelphia, Saunders. 
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An Overview of Methods for Labor Induction  
 
 The labor process, both in duration and onset, greatly varies across individuals. 
Preterm labor, classified as parturition prior to 37 weeks of gestation, may cause fetal 
distress. Similarly, post-term labor, classified as parturition after 40 weeks, poses a risk to 
fetal wellbeing due to insufficient nutrition derived from the placenta. In cases of fetal 
distress, maternal distress, or postdate pregnancy, providers often employ a range of 
different methods to induce labor. The first step in labor induction revolves around 
ripening the cervix. Promoting the cervix to absorb water and become more malleable 
increases the chances for successful vaginal delivery. Mechanical approaches such as 
inserting a balloon catheter to apply direct pressure on the cervix may be used to ripen the 
cervix (Tenore, 2003). The primary pharmacological method for induction of labor 
involves cervical ripening by misoprostol (Cytotec) and promotion of uterine contraction 
via Pitocin, a synthetic version of oxytocin. Alternative methods, particularly herbal 
methods indicated in inducing labor includes blue cohosh, raspberry leaf, evening 
primrose, and castor oil. Comparing the mechanism and the possible interactions of both 
the pharmacological method and alternative methods elucidates on the importance of 
using scientifically backed methods to ensure the safety of the expectant mother and the 
baby.  
 
 
 
56 
 
Herbal Supplements as Labor Inducers  
 
Many different herbal medications and preparations have been used by women to 
aid or induce labor. Of these, blue cohosh, red raspberry leaf, castor oil, and evening 
primrose make up the most common herbal supplements used for cervical ripening, 
induction, and augmentation of labor. The mechanism for both evening primrose and 
raspberry leaf remains relatively unknown. Little to no clinical research exists to help 
elucidate both the safety and efficacy of these two herbal medications. Only a handful 
clinical studies suggest that raspberry is a safe and effective method to induce labor, 
however, many of these trials are small with no statistically significant data (Hall et.al., 
2012). Caretakers still debate over the efficacy and safety of both evening primrose and 
red raspberry leaf. Due to a lack of research, pregnant women are often discouraged from 
taking these supplements.  
 Castor oil (Oleum Palmae Christi) is an ancient herbal medication derived from 
the seeds of Ricinus communis. Historically used to promote bowel movements and to 
treat inflammation, Castor oil has also been documented as a labor inducer in women at 
term. Ricinoleic acid, a hydroxylated unsaturated fatty acid, constitutes the main 
pharmacological mechanism of castor oil. Ricinoleic acid is a selective agonist of EP3, a 
prostaglandin receptor presents in both the small intestine and the myometrium. 
Consumption of castor oil and subsequently ricinoleic acid activates EP3 receptors on 
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smooth muscle cells in the uterus, thus initiating symptoms associated with labor (Tunaru 
et. al., 2012).  
Blue Cohosh (Caulophyllum thalictroides) is derived from a perennial plant with 
large blueberries. In the late 1990s, up to 64% of practicing midwives prescribed Blue 
Cohosh to induce labor and help speed up the process of delivery. However, several case 
reports suggest that Blue Cohosh may be associated with myocardial infarction, hypoxic 
injury, and cardiovascular birth defects (Dugoua et.al., 2008; Xia et al., 2014). The 
preparation of Blue Cohosh yields several important active constituents such as alkaloids 
and triterpene saponins. While these components show biological activity in anti-
inflammatory and analgesic effects, the exact mechanism for the induction of labor 
remains unknown (Xia et al., 2014). Blue Cohosh was shown to enhance estradiol 
binding to its receptors to increase the effect of estrogen, which may help initiate the birth 
process (Mills et.al., 2006).  
Interestingly, Cytotec shares a similar mechanism with castor oil, yet they wildly 
differ in terms of their regulation and standards. Both either directly or indirectly 
influences the expression and activity of prostaglandin, changing the motility of the 
uterus. Generally, castor oil and other herbal preparations remain grossly under-regulated 
by the FDA despite their pharmacologically active mechanisms. Comparison of Cytotec 
and other herbal alternatives yields somewhat of a paradox. Despite patchy empirical 
data, the FDA remains essentially quiet on herbal supplement regulations – adopting little 
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regulation requirements and quality standards. Conversely, despite ample clinical data 
suggesting the efficacy and safety of Cytotec as a labor inducer, the FDA has yet to 
officially approve the use to this drug for that indication. Despite consumer perception, 
both pharmacological and alternative methods operate under similar mechanisms, and 
thus, should be held to the same standards.   
Interactions Associated with Non-pharmacological Approaches  
 
 As with the case of herbal supplement raspberry leaf and evening primrose, 
because the main active constituents and pharmacological mechanism remain unknown, 
the potential for interactions with other compounds also remains unknown (Holst et.al., 
2009). Recently, studies on Blue Cohosh shows a whole slew of interactions and adverse 
side effects. Studies indicate that Blue Cohosh might constrict coronary arteries and a 
decrease in oxygen flow to the heart, thus, interacting with cardiovascular drugs such as 
nitroglycerin, that cause vasodilation (Mills et al., 2006). These symptoms and 
interactions remain relatively unexplored by researchers. In some ways, the increased 
potential for interactions with other medications and alternative methods makes these 
herbal medications more dangerous compared to other preparations and pharmacological 
drugs. Without even a foundation of knowledge about functionality, taking these herbal 
supplements in tandem with other drugs increases the change for severe interactions.  
 
 
 
59 
 
Misoprostol (Cytotec): A Pharmacological Drug to Induce Labor  
 
 As mentioned above, prostaglandins are a group of compounds that have a major 
effect on the labor process among other physiological processes. Misoprostol is a 
synthetic analog that induces many of the same effects. Cervical ripening can be induced 
by administering misoprostol orally or intravaginally. Prostaglandin administration 
induces collagenase activation, which breaks down collagen in the cervix causing the 
amount of collagen to be dispersed, resulting in a softer cervix. Application of 
misoprostol also induces extracellular matrix remodeling and promotes uterine 
contractions by sensitizing the myometrium to oxytocin. The use of this drug has been 
linked to uterine tachysystole or excessive uterine contractions and changes in fetal heart 
rate. Thus, proper monitoring of both maternal and fetal wellbeing remains an important 
part of labor management. Interestingly, misoprostol in the U.S. is only approved by the 
FDA for ulcer treatment. For the past 30 years, this drug has been used off label for labor 
induction and cervical ripening, and despite years of empirical data supporting the use of 
misoprostol in this role, no current FDA approval for this obstetrical indication exist. The 
American College of Obstetricians and Gynecologists (ACOG) endorses the use of 
misoprostol for induction, citing a large body of clinical evidence for its safety and 
efficacy (Stephenson & Wing, 2015). Pitocin, a synthetic form of oxytocin, may be 
titrated after cervical ripening to induce uterine contractions by increasing the 
intracellular concentration of calcium. Both Cytotec and Pitocin dosage needs to be 
stringently regulated to prevent polysystole and fetal tachycardia (Arias, 2000).   
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Interactions Associated with Pharmacological Approaches 
 
 The conversion of Misoprostol into its pharmacologically active constituents 
occurs in the stomach, thus the intake of food may alter its bioavailability. Thus, dosage 
of Misoprostol should be altered to account for its variable metabolism. Despite studies 
evaluating interactions between Misoprostol and NSAIDs (aspirin or ibuprofen) and other 
classes of drugs, no clinically significant or relevant interactions were reported. The use 
of misoprostol or Cytotec has no known drug interactions. Moreover, this 
pharmacological therapy does not interact with the CY P450 enzymatic system often 
indicated in drug metabolism and absorption (Davies et.al., 2001; Goldberg et.al., 2001). 
The Gap Between Pharmacological drugs and Herbal Supplements  
 
In this chapter, many different herbal supplements were examined for both safety 
and efficacy with variable and inconsistent results. Ginger, one of the most studied herbal 
supplements, yields promising results for usage during pregnancy. However, many of the 
other herbal supplements such as valerian root and blue cohosh yielded little data and 
potentially detrimental effects on both maternal and fetal systems. In comparison, the 
pharmacological counterparts provided providers and patients with extensive research on 
potential side effects for usage during pregnancy as well as efficacy. Despite containing a 
whole mixture of pharmacologically active ingredients, herbal supplements remain 
largely underregulated.  
 
 
61 
 
 A clear discrepancy in knowledge for the mechanism of action directly stems 
from the difference in FDA regulation between pharmacological therapies and herbal 
remedies. While drugs are required to pass premarket benchmarks, herbal supplements 
adhere to no standardization or premarket regulations or tests. However, this is almost 
like a double edge sword. Stringent testing on safety and efficacy aims to protect patients 
from adverse side effects, public misconceptions on data and research may deter progress 
in treatment.  
The litigation and history of Bendectin, now marketed as Diclegis serves as a prime 
example of how proper scientific and clinical research corresponds with public 
misconceptions. After obtaining FDA approval in the 1950s, the doxylamine-pyridoxine 
combination became widely prescribed. At the peak of use, almost 25% of women 
reported taking this drug to manage NVP. However, coinciding with the Thalidomide 
tragedy, the safety of Bendectin came under scrutiny by a skeptical public in the late 
1960s and into the 1970s. Eventually, a slew of lawsuits came in claiming that Bendectin 
as a teratogen, causing multitudes of birth defects in infants across the country. The 
pharmaceutical company elected to remove Bendectin from the market, based on weak 
claims unbacked by scientific studies. Shortly after, independent studies dispelled the 
claims that the doxylamine-pyridoxine caused fetal deformities, affirming the 
effectiveness and safety of Bendectin. However, this combination was only recently 
introduced back into the pharmaceutical market. A 30-year gap between the removal and 
 
 
62 
 
reintroduction of this highly effective drug left obstetric care with no FDA approved 
medication to mediate NVP (Slaughter et. al., 2014).   
Between the case studies with herbal supplements and pharmacological drugs, 
clearly, there is an inconsistency in the effectiveness of FDA regulation. On one hand, 
most herbal supplements remain largely underregulated and hence understudied. With 
increasing popularity and usage, this potentially leads to different drug-herb interactions 
and adverse side effects. On the other hand, stringent regulations on pharmacological 
drugs limit the ability for the development of new techniques. Another major component 
in regulation involved the public’s perception and understanding of the mechanisms and 
effects of both pharmacological therapies and herbal therapies alike. Perhaps the notion 
that herbal supplements are natural deters patients from investigating their mechanism 
and side effects while pharmacological drugs are often viewed as unnatural and 
associated with teratogenic effects. These preconceptions change the way the general 
public interprets the data and regulations set by the FDA. An effective regulatory system 
for both herbal supplements and pharmacological therapies should involve premarket 
approval, disclosure of all physiological effects, and standardization while considering 
the perspective of the general population. 
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Chapter 4.1: The Complexity of Postpartum: Pharmacological and Herbal 
Therapies in Treating Postpartum Depression (PPD) 
 
Hormonal Changes Associated with PPD   
 
In the days and weeks following childbirth, a woman’s body undergoes 
significant physiological changes. Due to a dramatic decrease in weight, changes in social 
and family dynamics, and hormone fluxes, women typically experience a wide range of 
emotions, which can include a persistent depressive mood. One of the most expensive 
diseases to treat in America is depression, with over 14.8 million adults suffering from at 
least one major depressive episode in any given year (DBSA, 2016). PPD exists as a 
subset of depression affecting women anytime within the first four weeks of the 
postartum period to 8 weeks postpartum, affecting anywhere from 7% to 20% of all 
women who gave birth (Schiller, Meltzer-Brody, & Rubinow, 2015). Some of the most 
common symptoms of PPD include a persistent depressed mood, a decrease in interest of 
leisure activities, and disturbances in appetite or sleep (Solomon & Bauer, 2018). 
Research shows that the development of PPD is multifactorial, relying on a combination 
of social and biological factors (McCoy, Beal, Miller Shipman, Payton, & Watson, 2006). 
After giving birth, a woman’s body undergoes drastic biochemical changes in the form of 
gonadal hormones, thyroid hormones, and pituitary hormones fluxes, causing a whole 
array of varying symptoms. Changes in these the biochemical processes combined with 
environmental stressors such as lack of support or marital conflict may lead to the 
development of PPD. 
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With such a high prevalence and increasing occurrence of PPD in routine OB/Gyn 
care, PPD is a major health concern affecting the patient and their immediate social 
groups. PDD, like major depressive disorder, can be treated using a combination of 
intervention by medical personnel and medication. Understanding the biochemical 
changes will help us elucidate out how herbal supplements and pharmaceuticals can 
influence the signaling pathways.  
Gonadal Hormones Changes  
 
Hormones such as estrogen, progesterone, follicle stimulating hormone (FSH), 
and luteinizing hormone (LH) play a large role in maintaining homeostasis and 
reproductive function. On a more general level, these hormones also play a large role in 
the regulation of emotion, arousal, and motivation. During pregnancy, estrogen and 
progesterone levels are elevated, largely because of placental production and 
contribution.  
Estrogen exists as two main biologically active compounds: estradiol and estriol, 
which increase in pregnancy from basal levels by 100-fold and 1,000-fold respectively. 
However, estrogen levels crash after birth, returning to preconception levels by day five 
of postpartum (Hendrick, Altshuler, & Suri, 1998). This sudden change in levels 
correlates to the development of PPD and its associated symptoms both directly and 
indirectly. Because of its role in controlling emotion, the sudden decrease in estrogen 
correlates to the development of a persistent depressed mood that is also influenced by 
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psychological and social risk factors. Estradiol (E2), an active form of the hormone 
estrogen plays an interesting role in the regulation of different biological systems and 
pathways in the body. The presence of estradiol directly correlates with the function of 
the serotonin, a potent neurotransmitter implicated in the regulation of euphoria. E2 
increases the production of tryptophan hydroxylase, an important enzyme in catalyzing 
the formation of serotonin from tryptophan. During the sharp decline in estrogen levels, 
the levels of serotonin also decrease. In addition, E2 inhibits the expression for the gene 
responsible for the reuptake of serotonin, allowing the neurotransmitter to increase its 
activity in the synapses. The decrease in the E2 levels after birth increases the reuptake of 
serotonin immediately after birth. Reuptake decreases the activity of these 
neurotransmitters, leading to both mental and physiological symptoms such as fatigue 
and a decrease in enjoyment of activities (McCoy et al., 2006; Rybaczyk et al., 2005).  
Progesterone, another prominent gonadal hormone implicated in reproductive 
function, also experiences significant fluctuations throughout the pregnancy and the 
postpartum period. Following successful implantation of the zygote in the uterus, the 
levels of progesterone remain high throughout the duration of the pregnancy both through 
maternal and fetal contributions. This steroid hormone suppresses the maternal immune 
system against fetal antigens and maintains the proper environment during embryo-
development. On a more global scale, progesterone increases the activity of GABA 
receptors, which are ion channels that govern the flow of ions into the cell. Increased 
activity of GABA receptors decreases the excitation of the neuron, which can help 
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decrease and modulate feelings of anxiety or fear. After the delivery of the placenta, the 
levels of progesterone sharply decline during the postpartum period. Progesterone 
withdrawal during the postpartum period can contribute to the anxiety symptoms seen in 
PPD (McCoy et al., 2006; Tuckey, 2005).  
Thyroid Hormones Changes  
 
           Interestingly, studies indicate that in the 6 months following delivery, new 
mothers experience a higher incidence rate of thyroid dysfunction at around 7% 
compared to the general population, whose incidence rate lies at around 3% to 4% 
(Hendrick et al., 1998). The thyroid secretes differing levels of thyroid hormones to 
regulate metabolism, temperature, heart rate, and the production of energy in the form of 
ATP (Gnocchi, Steffensen, Bruscalupi, & Parini, 2016). Scientists hypothesize that 
abnormalities in thyroid hormone concentration may serve as an indicator for the 
development of major depression as thyroid dysfunction is often accompanied by 
depression (Schiller et al., 2015). While the development of PPD isn’t directly correlated 
with the presence of thyroid hormone abnormalities in most women, it appears to be a 
significant factor for a certain subset of mothers (Hendrick et al., 1998).  
           Changes in thyroid hormones during pregnancy and levels of estrogen interacts 
via biochemical flux. During pregnancy, as mentioned before, the levels of estrogen 
remain elevated due to fetal contributions. This substantial gonadal hormone increase 
also causes an elevation in the levels of thyroxine-binding globulin (TBG) and 
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consequently, leading to a surge in circulating T4 levels, which is the inactive form of the 
TH (Schiller et al., 2015). In addition, a placental contribution in producing excess 
thyroid stimulating factors and an overall iodine deficiency may also contribute to a net 
increase in T3/T4. In the case of diminished thyroid function, often referred to as 
hypothyroidism, studies indicate a decrease in the amount of serotonin activity (Engelsen, 
Fern, Ireland, Harris, & Silver, 2015; Hendrick et al., 1998).  
Pituitary Hormones Changes  
 
           During the pregnancy and the birthing process, the increased levels of stress cause 
a substantial elevation in levels of corticotropin-releasing hormone (CRH) and 
adrenocorticotropic hormone (ACTH), leading to hyperactivation of the HPA axis. The 
HPA axis or the hypothalamus-pituitary-adrenal axis is one of the major endocrine 
pathways that influence our stress hormones. Activation of this pathway leads to a 
response in by the sympathetic nervous system, activating our fight or flight response by 
increasing the amount of cortisol released. The levels of cortisol, a hormone involved in 
activating the stress response in the body, sees a significant drop approximately our days 
after delivery. Yet, the HPA axis takes approximately 12 weeks postpartum to return to 
normal function. This dysfunction in the regulation of cortisol may link hormonal 
imbalance immediately following birth to the development of PPD (Schiller et al., 2015). 
The stress hormone fluctuation is hypothesized to contribute to clinical symptoms 
observed in PPD.  
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Treatment of PPD: An Overview of Common Pharmacological Drugs and Herbal 
Supplements  
 
           PPD and depression, in general, can usually be treated using a combination of 
psychotherapy and medications, such as selective serotonin reuptake inhibitor (SSRI). 
These drugs work by decreasing the activity of molecules that remove serotonin, which is 
a neurotransmitter linked to the feelings of euphoria, from the area between a synapse. 
This allows for a prolonged increase in the levels of serotonin in the brain, which can 
help increase its activity and alleviate symptoms typically observed in depression 
(Schafer, 1999). Many of the SSRI’s available, such as fluoxetine or Nefazodone, have 
been clinically approved for use during the postpartum period (Weier & Beal, 2004). 
However, there is still a lack of research on the effects these antidepressant medicines 
have during prolonged usage in mothers who elect to breastfeed. Most of the 
antidepressant medications are excreted out via the breast milk, and while only a few 
reports indicate a maladaptive effect on the infant, there is a lack of research on the exact 
effect of the effect on the medication transmitted through the breast milk. Due to these 
perceived effects, there seems to be an increasing number of women turning toward 
alternative modes of treatment. Herbal supplements present as a potential alternative 
treatment for postpartum depression. St. John’s Wort emerges as a common herbal 
medication used in the postpartum period to treat PPD. However, on top of the holes in 
the FDA regulations of herbal supplements, the efficacy and safety of St. John’s Wort 
may pose a health risk to both the mother and the baby. A comparison between the 
 
 
69 
 
mechanism and the potential interactions of St. John’s Wort and Prozac (fluoxetine) can 
help us elucidate a proper way to regulate their usage.  
Non-Pharmacological Therapies for PPD 
St. John’s wort (SJW) is a common herb often used to treat mild to moderate 
depression, in place of other pharmaceutical medications such as SSRI’s. Some women 
opt to take SJW rather than a pharmaceutical drug in the postpartum period, citing that 
the use of this supplement may be safer because it is thought not to affect the breast milk 
as much. In vivo studies indicate that extracts of Hypericum perforatum, what is 
commercially known as SJW, serves as an effective treatment for symptoms associated 
with mild. However, the pharmacological mechanism for SJW is unknown, due to a 
complex mixture of compounds in this supplement and the variability in its purity across 
brands(Butterweck & Schmidt, 2007; Linde, 2009). 
Initially, the mechanism of this herbal supplement was hypothesized to induce the 
inhibition of both type A and B monoamine oxidase (MAO), which are responsible for 
the catabolism of biogenic amines. However, while MAO inhibitors are present, this has 
been proven to be a minor effect and it doesn’t constitute the whole mechanism employed 
by SJW (Butterweck, 2003; Butterweck & Schmidt, 2007).  
The leading theory now suggests that Hyperforin, a major active constituent of 
SJW, unselectively inhibits the reuptake of neurotransmitters such as serotonin and 
dopamine. While the exact mechanism remains unclear, SJW is hypothesized to 
indirectly decrease the reuptake of neurotransmitters by changing the permeability of the 
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Na+/H+ channels to increase intracellular Na+ levels. Normally, in a neuron, which is a 
specialized nerve cell in the body, there is a net negative charge in the membrane 
potential. For this cell to transmit a signal, a flow of different ions, such as Na+, K+, and 
Ca2+, fluctuates to flip the charge from an overall negative charge to a positive charge. 
The ability of a neuron cell to create this change allows for the cell to function and rely 
that message on to other cells. The reuptake system of serotonin is inhibited by the influx 
of sodium, thus, hyperforin non-selectively inhibits this system, which is a mechanism 
similar to that of SSRI’s. (Butterweck & Schmidt, 2007; Carlo, Borrelli, Ernst, & Izzo, 
2001; Linde, 2009; Singer, Wonnemann, & Muller, 1999).  While Hyperforin currently 
remains as the main mechanism for the effects of SJW, there could be additive effects 
from the other active constituents.  
Pharmacological Therapies for PPD 
 
In terms of pharmacological methods, pp to 35% of women use psychotropic 
medications during pregnancy and in the postpartum period. One of the most commonly 
prescribed psychotropic medicine during pregnancy is Prozac, drug apart of the larger 
family of SSRI’s. The widespread usage of these medications Prozac and other SSRI’s 
readily passes through the placental barrier during pregnancy and diffuses into the 
breastmilk because of their relatively hydrophobic structures. This leads to discussions 
about the safety of these medications not only for maternal health but also how these 
drugs can affect infant neurobehavior or induce potential teratogenic effects in utero. 
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Prozac, like most SSRI’s, inhibit the molecules responsible for the reuptake of 
neurotransmitters such as serotonin, leading to an increase in concentrations of these 
molecules at the synaptic cleft (Zeskind & Stephens, 2004). 
Despite different chemical compositions, SJW and Prozac employ similar 
mechanisms to modulate the symptoms of PPD. Hyperforin, the major active component 
in SJW, and Prozac, which is classified as an SSRI, modifies the levels of 
neurotransmitters such as serotonin by altering the activity of the enzymes responsible for 
the reuptake of these molecules. The etiology of PPD, similar to other mood disorders, 
draws from multiple variables including hormonal and biochemical changes within the 
body and social environments. The use of medications such as SJW and Prozac helps 
curb the clinical symptoms on a biological level. 
Risks/Interactions Associated with Nonpharmacological Methods  
 
           Due to several active components, SJW may interact with different herbal 
supplements and pharmaceutical drugs when taken in tandem. There are two main types 
of drug-drug or herb-drug interactions: pharmacokinetic interactions, which refers to drug 
absorption, distribution, metabolism, and excretion and pharmacodynamic interactions, 
which refers to the relation between the concentration of the substance and its effect 
(Pharmacokinetics, 1985). One of the most pertinent interactions revolves around 
pharmacokinetic interactions with Cytochrome P450 (CYP), a superfamily of enzymes 
crucial for the metabolism of drugs and detoxification of chemicals. SJW is a known 
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inducer of CYP enzymes. (Lin & Lu, 1998; Thompson, 1839). Many different drugs and 
compounds interact with the mechanism of CYP enzymes within the body and because 
SJW alters the activity of these enzymes, it can modulate the effects of other drugs. For 
example, SJW significantly reduces the pharmacological effects of Warfarin, a common 
blood thinner because the induction of the CYP enzymes leads to increased clearance of 
the drug. This leads to serious health risks because it increases the likelihood of 
developing blood clots that leads to DVT or stroke. Similarly, studies indicate that SJW 
changes the levels of other drugs such as anti-HIV drugs, antiepileptic drugs, 
hypoglycemic drugs, benzodiazepines, among other classes of drugs (Borrelli & Izzo, 
2009; Thompson, 1839).   
 Interestingly, CYP enzymes also play a major role in the formation and 
metabolism of estrogen within the body. Aromatase, a specific CYP enzyme, mediates 
the synthesis of estrogen and the management of the oxidative states of estrogen relies on 
another set of CYP enzymes. Drugs that induce CYP enzymes may affect increase the 
hydroxylation of estradiol, hence changing the activity of estrogen in the body. These 
changes increase the risk for the development and the persistence of PPD in mothers. 
While this area remains less studied, SJW, due to its influence on CYP enzymes may 
change the symptoms of PPD by altering the levels of estradiol (Martucci & Fishman, 
1993). 
Risks/Interactions Associated with Pharmacological Methods   
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Prozac also exhibits inhibitory action against multiple isoforms of the CYP 
enzymes. The inhibition of these enzymes leads to pharmacokinetic features such as a 
decrease in clearance of secondary drugs, precipitation of more severe side effects, and 
an increase in the likelihood of toxicity. Prozac, when taken in tandem with other SSRI’s 
or other antidepressants, can cause a significant surge in serotonin levels, leading to 
serotonin syndrome. The inhibition of CYP also alters the metabolism of larger classes of 
drugs including cardiovascular drugs and other SSRI’s. On the other hand, Prozac has 
also been shown to blocking the conversion of drugs into their active components. This 
specific SSRI prevents the conversion of codeine and tramadol, two common analgesic 
drugs, into their active components. This significantly reduces the efficacy of analgesic 
drugs, causing patients to experience increased pain (Gillman, 2005).  
In addition to maternal effects, the ability of Prozac to diffuse across the placental 
barrier and the breastmilk exposes infants to these same effects. Exposed infants 
experience an elevation in levels of serotonin, which can cause a wide variety of 
physiological symptoms such as more generalized erratic motor activity and tremors 
(Zeskind & Stephens, 2004). The potent interactions between Prozac with other SSRI’s 
and substances warrants careful regulation by the FDA.  
While proven to be relatively effective, these medications are not without 
significant risks. Due to their similar mechanisms, SJW and Prozac alter the clearance of 
other drugs by influencing the activity of CYP, leading to impaired function or an 
exacerbation of symptoms. It remains imperative to report usage of both pharmaceutical 
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drugs, but also herbal medications to healthcare providers. This allows physicians to 
modulate possible interactions with other medications. 
Comparing the Preparation and Regulation of SJW and Prozac  
  
Despite their similarities in function and effect, these SJW and Prozac drastically 
differ in terms of their preparation methods and regulation. Prozac falls under the 
umbrella of pharmaceutical drugs, which requires much stricter regulations on the 
concentrations of the active component present. In contrast, SJW and other herbal 
medications operate under lax regulations. The concentrations of components in SJW are 
not regulated, varying depending on the preparation style. Typically, air-dried H. 
perforatum L. flowers and buds are soaked in 60%-80% methanol for approximately 30 
minutes to extract out the lipophilic components found in the flower. The identified 
components in the final product of SJW fall under several categories: 
naphthodianthrones, flavonoids, hyperforin, and water-soluble components. The 
concentration and proportions of each constituent vary depending on the duration, 
harvesting, a light exposure environment (Butterweck & Schmidt, 2007), hence leading 
to great variability in products with a lack of FDA oversight. Different brands of SJW can 
contain different substituents, which can alter the effect of other drugs and increase the 
risk for unforeseen interactions. With so many prominent similarities, the regulation of 
both substances should be altered to mirror each other, thus decreasing the associated 
risks of interactions with other medications.  
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Chapter 4.2: The Complexity of Lactation: Pharmacological and Herbal Therapies 
to Treat Insufficient Milk Supply 
 
Biochemical Changes Involved in Lactation 
 
 A major component of the postpartum period revolves around breastfeeding. 
Studies indicate that breastfeeding is the optimal form of nutrition for infants, providing 
both short term and long-term benefits to the baby. These benefits include immunological 
effects and decreased risks for diseases such as gastroenteritis, obesity, and type I and II 
diabetes. Breastfeeding also shows signs of enhancing the maternal-fetal emotional bond. 
Overall, breastfeeding provides significant benefits to the mother and provides the best 
health, psychological, and developmental outcomes for the infant. However, the duration 
of exclusive breastfeeding and lactation by the mother remains varied due to many 
different circumstances (Conover & Buehler, 2004; Mannion & Mansell, 2012). The 
development and secretion of milk by the mother relies on biochemical changes in the 
body.  
  Mammary glands, which are essentially modified sweat glands modulated by the 
endocrine system, plays a major role in both lactation and secretion. Lactocytes, milk-
producing cells, line the alveoli of the mammary gland, located within the breast and 
serve as the main site of milk production. The blood capillaries that surround the alveoli 
of the gland provides a system for substrates such as vitamins and glucose to diffuse 
across the cell membrane of the lactocytes to be integrated into milk components. 
Interestingly, while the same basic components of the milk remain constant, diet plays a 
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huge role in dictating the energy content of the milk as well as the vitamin and mineral 
content (Hoehn & Marieb, 2016; Kent, 2007). While the vascularization of this area 
allows for easy diffusion of milk components and vitamins, it also makes the diffusion of 
lipid-soluble substances such as herbal supplements easier.  
Lactogenesis I and II  
 Lactogenesis or the production of milk secretions is mediated primarily by 
prolactin, a hormone secreted by the anterior pituitary gland. The main steps in 
lactogenesis can be summed up into two main stages lactogenesis I and lactogenesis II. 
The first stage typically begins between weeks 16 and 22. During this phase, the 
mammary glands begin development (Kent, 2007; Zapantis, Steinberg, & Schilit, 2012). 
The second stage, or lactogenesis II, typically occurs immediately after birth. 
Characteristic of significant milk production and secretion, this phase typically relies on 
fluctuations in the concentrations of certain pituitary hormones. A significant increase in 
prolactin, insulin, and adrenal cortisol in combination with a progesterone withdrawal in 
the postpartum period allow for the activation of copious milk secretions (Kent, 2007). 
This change is typically noted by a sudden feeling of fullness in the breasts.  
Biochemical Changes Involved with Secretion  
 
 Another prominent hormone apart of this system involves oxytocin, which also 
causes uterine contractions to initiate and propagate the birthing process. In a process 
referred to as “let down,” a spike in oxytocin influences the expulsion of milk from the 
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breast. Suckling or stimulation of the nipple area activates sensory afferent neurons, 
sending a signal that prorogates to the anterior pituitary gland. The stimulation of this 
gland causes the release of oxytocin. Once this hormone reaches the mammary gland, via 
the bloodstream, oxytocin acts on the contractile cells surrounding the alveoli causing the 
release of breast milk. While direct stimulation via sucking by the infant remains the 
primary trigger for this response, schedule of feeding or even merely the sight of the baby 
can cause this reflex to activate. Thus, hormonal imbalance, especially in the levels of 
oxytocin may result in alterations of the release of the milk (Hoehn & Marieb, 2016; 
Newton & Newton, 1950).  
Herbal Supplement Usage during Lactation  
 
 A common problem during the breastfeeding stage, which can last over a year 
postpartum, revolves around perceived insignificant milk supply. Most often, this issue 
results from improper breastfeeding techniques, but can also be the product of maternal 
hormone imbalance or deficiency in the breast tissues. If breastfeeding techniques, such 
as latching, are ruled out, the use of galactagogues can be used to increase the production 
or flow of milk. Galactagogues can include foods, herbal medications, and 
pharmaceutical drugs (Hoehn & Marieb, 2016; Westfall, 2003; Zapantis et al., 2012). 
Hundreds of plant species have been used to increase milk production, however, despite 
centuries of usage by women worldwide, most of these substances remain unproven in a 
lab or clinical setting. 
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Table 4: Common herbal medications used during the lactation period.1 (Yildirim, 
Desdicioglu, Kara, & Yavuz Avsar, 2016), (Mannion & Mansell, 2012)  2 (Westfall, 
2003), (Mannion & Mansell, 2012), 3,4 (Mannion & Mansell, 2012). 
Herbal Supplement  Reason for 
Use  
Benefits  Associated 
Risk  
Interactions 
Fenugreek 1 
 
 
 
To stimulate 
the 
development of 
breast milk  
Stimulates 
oxytocin 
secretion 
to help 
induce 
labor  
Hypoglycemic 
effects, 
hepatoxicity, 
diarrhea 
Potential 
interactions 
with 
anticoagulant 
medication 
and 
antidiabetic 
medicine  
Fennel 2 
 
 
 
Expectorant, 
Upper 
respiratory 
tract infection, 
antispasmodic, 
galactagogue  
Digestive 
aid, mild 
estrogenic 
properties  
Seizures, 
nausea, 
pulmonary 
edema  
Can interact 
with 
anticonvulsant 
medications  
Blessed Thistle 3 
 
 
 
Stimulates 
menstruation, 
antidiarrheal, 
expectorant, 
galactagogue   
 Nausea, 
vomiting, 
diarrhea, 
contact 
dermatitis  
May interfere 
with antacids, 
H2 
antagonists, 
proton pump 
inhibitors, 
insulin  
Anise 4 
 
 
 
Expectorant, 
antispasmodic, 
antiseptic, 
antiflatulence  
 Seizures  Interactions 
with 
anticoagulants, 
MAO 
inhibitors, and 
oral 
contraceptives  
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Out of the hundreds of herbal galactagogues, the most commonly used one is 
Fenugreek. Historically, this plant, originating from India and Northern Africa has been 
used to treat a range of aliments from induction of labor to digestion to cough (Ulbricht et 
al., 2007). The preparation of this herbal supplement typically includes the addition of 
saponin, alkaloids, amino acids, coumarin, among other ingredients (Abebe, 2002). Due 
to minimal regulation by the FDA, the concentrations of these components vary, altering 
the efficacy and safety of fenugreek supplements.   
 The main mechanism of Fenugreek remains unknown and poorly documented, 
moreover, the active ingredients have not been identified. Scant clinical trials have yet to 
establish the safety of efficacy of Fenugreek usage during pregnancy or the lactation 
period. It is hypothesized that Fenugreek stimulates sweat production, which may affect 
the function of the mammary glands, which are essentially just modified sweat glands. 
Fenugreek might also contain estrogenic activity. This herbal supplement contains 
estrogen-like compounds that can increase the levels of phytoestrogens, dietary estrogens 
that can potentially bind to estrogen receptors, altering the functionality of the endocrine 
system (Gabay, 2002; Mortel & Mehta, 2013).  
Risks and Interactions Associated with Nonpharmacological Methods  
 
 Typically, Fenugreek is well tolerated with no serious side effects. However, 
when taken with some pharmaceutical drugs, this herbal supplement may exacerbate the 
effect of medications when taken in tandem. Fenugreek may interfere with hormone 
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therapy, due to its estrogen like-components. Moreover, studies have shown that 
Fenugreek may interfere with the function of diabetic drugs such as insulin as well as 
corticosteroids. 4-hydroxyisoleucine, one of the active components in Fenugreek, may 
directly stimulate insulin release, which complicates the metabolism of patients with 
diabetes and their insulin dosage (Mills et.al., 2006).   
Pharmaceutical Drugs for Milk Production  
 
 Metoclopramide and domperidone constitute the main drug therapies currently 
available for the stimulation of milk production. Both of these substances act by acting as 
a dopamine antagonist, which subsequently increases prolactin release. A surge in 
prolactin signals for increasing production of milk, however, this method only addresses 
underlying hormone imbalance that may cause a decrease in milk production. Once other 
factors, particularly poor latching techniques, are addressed, physicians can prescribe a 
regiment with metoclopramide and domperidone to promote milk production. (Gabay, 
2002; Osadchy et.al., 2012; Westfall, 2003; Zapantis et al., 2012). Case studies indicate 
that the usage of metoclopramide shows an increase in a decrease in milk sodium 
concentration, but more prominently, a significant increase in both prolactin levels in the 
blood and a prominent increase in daily milk production (Gabay, 2002).  
 In comparison, Domperidone utilizes a similar mechanism as a dopamine 
antagonist, this increasing the prolactin levels in the blood. However, rather than having 
central pharmacologic effects, Domperidone has a larger effect on the periphery 
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dopamine release system. Due to lower lipid solubility and a larger molecular structure, 
Domperidone exhibits a decreased ability to cross the blood-brain barrier. With a lower 
diffusion rate, this drug seems to exhibit less influence on motor neuron function 
compared to Metoclopramide and less overall diffusion into the breast milk. While 
domperidone is typically intended for use as an antiemetic to treat reflux disease, this 
medication is often used as a galactagogue without the presence of serious side effects 
(Gabay, 2002; Mannion & Mansell, 2012). 
Risks/Interactions Associated with Pharmacological Methods  
 
 In 2004, the FDA issued a warning against the usage of Domperidone as a 
galactagogue. Citing reports of arrhythmia, QT prolongation, and hypokalemia, the U.S. 
bans the usage of this drug for milk enhancement. Domperidone remains available 
internationally and is embraced by other countries as an effective therapy for milk 
production (Osadchy et al., 2012). Domperidone has been shown to be a weak inhibitor 
of CYP3A, a specific enzyme apart of the CYP superfamily important in the clearance of 
certain drugs. Thus, Domperidone may increase the exposure to drugs cleared by CYP3A 
(Chang et.al., 2010).  
 Metoclopramide, a central dopamine antagonist, may cause drowsiness, fatigue, 
insomnia, depression, and pseudo-Parkinsonism. Due to its ability to pass into the breast 
milk, prolonged clearance of this drug into infants result in high serum levels, increasing 
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the risk for methemoglobinemia (increased methemoglobin levels in the blood) (Mannion 
& Mansell, 2012).  
Comparison Between Pharmacological Drugs and Herbal Supplements  
 
 In comparison to pharmacological therapies, fenugreek along with many other 
galactagogues presents with questionable efficacy for stimulating the production of 
breastmilk. With little clinical evidence, the usage of herbal galactagogues propagates 
through individual accounts and case studies. Moreover, most of these herbal products 
operate using an unknown mechanism. In contrast, pharmaceutical drugs, mainly 
Domperidone and metoclopramide, presents strong clinical and mechanistic evidence for 
efficacy in stimulating milk production. Despite their differences, active components in 
both herbal and pharmaceutical galactagogues can directly conflict with other 
medications to cause adverse side effects. However, similar to the situation between the 
regulation of herbal supplements and pharmaceutical drugs to treat PPD, the regulation 
between substances used for stimulation of milk production also shows distinct 
discrepancies. Herbal supplements require no premarket approval, empirical support, nor 
do they require a prescription to obtain. In contrast, pharmacological drugs are required 
to complete several rounds of clinical trials before being approved for distribution. These 
drugs are also required to adhere to rigid production standards and labeling requirements. 
As mentioned earlier in this chapter, herbal supplements and pharmacological can induce 
a whole host of biochemical interactions, leading to physiological symptoms.   
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Chapter 5: Empowering Women to make the Best Treatment Choice During 
Pregnancy, Birth, and Beyond 
 
 While there seems to be a social distinction between herbal supplements and 
pharmacological treatments, I hope that through this thesis, I effectively challenge this 
notion. Scientific data suggests that herbal supplements can employ a similar 
physiological effect and induce interactions with other substances, just like any 
pharmacological drug. Yet, the lack of government regulation and the skewed media 
presentation of herbal supplements buries the associated risks and effects.  
After stepping through how the hormonal fluctuations impart a multitude of 
symptoms and how medications, both pharmacological and herbal, influence hormonal 
and biological homeostasis, the overarching question is should herbal supplements be 
used or even recommended. In other words, do the benefits of herbal supplements 
outweigh the risks? I argue that in most cases, the risks actually outweigh the benefits. 
There is a lack of reliable information and the risks of taking these supplements remain 
widely unknown. Especially for women who must balance their own health with their 
baby’s health, this poses a huge health dilemma. Researchers and providers alike should 
work to close the gaps in knowledge and provide women with a solid scientific 
foundation to make informed decisions on medication regiments.   
While I cannot offer definitive answers or methods to solve this issue, I believe 
that there are two main directions we can take to advocate for change in the regulation 
and perception of herbal medications. This shift needs to be initiated by health care 
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professionals in the examination room. Healthcare providers need a higher and more 
global understanding of women’s current perspective on using alternative medicine. With 
a more holistic point of view, physicians can change the culture around herbal medicine 
by creating a safe space for patients to voice questions or concerns. In many ways, this 
reflects the Jesuit mission of Cura Personalis, a Latin term that translates to “care for the 
entire person.” Extending on the Hippocratic oath of “do no harm”, under Cura 
personalis, doctors are responsible for not only harm reduction but also acknowledging 
and treating all aspects of the person. Alternative and herbal medicine is deeply ingrained 
in many different cultures and thus plays an important part in a patient’s choices and 
views.   
The second avenue that can change the perception of alternative medicine lies 
within scientific communication, particularly the media portrayal of these substances. A 
quick Google search yields thousands of results, with most of the top hits consisting of a 
number of blog posts with personal stories on the success of herbal supplements curing 
different diseases or symptoms. Often times, these anecdotal stories portray herbal 
supplements as completely harmless. While there are proven merits to certain herbal 
supplements, many of them, as denoted earlier have serious side effects. Scientists can 
take on a larger role in educating the general public. Publishing empirically supported 
articles in different magazines and journals help provide a more accurate portrayal of 
herbal supplements and can help raise awareness of the lack of information on their 
mechanism.  
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The use of herbal medicine and alternative medicine in the U.S. bisects both 
physiology and biochemistry with cultural influences such as tradition. The dialect and 
communication between researchers, health care providers, and patients are critical in 
navigating the different paths possible. We shouldn’t shy away from herbal supplements 
and alternative medicine, but rather, we should encourage conversation about them. I 
hope that this thesis serves as a tool to spark the conversation.  
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List of Abbreviations 
 
ACOG   American College of Obstetricians and Gynecologists  
ACTH   Adrenal corticotropic hormone  
CAM   Complementary alternative medicine  
CL   Corpus luteum  
CRH   Corticotropin-releasing hormone  
CYP   Cytochrome P450 
DSHEA  Dietary Supplement Health Education Act of 1994   
DVT   Deep vein thrombosis  
E2   Estradiol  
FDA   Food and Drug Administration  
FDCA   Food, Drug, and Cosmetic Act  
FSH   Follicle stimulating hormone  
GABA   gamma-Aminobutyric acid 
hCG   Human chorionic gonadotropin hormone 
HPA   Hypothalamus-pituitary-adrenal axis   
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hPL   Human placental lactogen  
IRCH    International Regulatory Cooperation for Herbal Medication  
LH   Luteinizing hormone 
NSAIDS  Nonsteroidal Anti-inflammatory Drugs  
NVP   Nausea and vomiting of pregnancy  
OTC   Over the Counter  
PPD   Postpartum Depression  
REM   Rapid eye movement sleep  
SJW   St. John’s Wort  
SSRI    Selective Serotonin Reuptake Inhibitor  
TBG   Thyroxine-binding globulin  
TH    Thyroid hormone  
UTI   Urinary tract infection  
WHO    World Health Organization  
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